Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

Christopher L. Morton, Peter J. Houghton, E. Anders Kolb, Richard Gorlick, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background. Seneca Valley virus (NTX-010) is a nonrecombinant, replication competent RNA virus that is undergoing phase 1 clinical trials in adults for tumors with neuroendocrine characteristics. Here we have evaluated the antitumor activity of NTX-010 administered systemically. Procedures. In vitro NTX-010 was tested against 23 cell lines exposed for 96 hr at 1 × 10-4 to 104 viral particles (vp)/cell. In vivo NTX-010 was administered intravenously once at 3 × 1012 vp/kg. Three measures of antitumor activity were used: (1) an objective response measure modeled after the clinical setting; (2) a treated to control (T/C) tumor volume measure; and (3) a time to event (fourfold increase in tumor volume for solid tumor models), measure based on the median event-free survival (EFS) of treated and control animals for each xenograft. Results. In vitro NTX-010 demonstrated a marked cytotoxic effect in a subset of the cell lines from the neuroblastoma, Ewingsar coma, and rhabdomyosarcoma panels. In vivo the most consistent activitywas observed for the rhabdomyosarcoma and the neuroblastoma panels, with all four of the alveolar rhabdomyosarcoma xenografts and four of five neuroblastoma xenografts achieving CR or maintained CR. Objective responses were also observed in the rhabdoid tumor,Wilms tumor, and glioblastoma panels. Conclusions. NTX-010 demonstrated a high level of activity both in vitro and in vivo. Further analysis of existingtestingand molecular characterization data may help define the biological characteristics of cancer cells that are associated with response to NTX-010.

Original languageEnglish (US)
Pages (from-to)295-303
Number of pages9
JournalPediatric Blood and Cancer
Volume55
Issue number2
DOIs
StatePublished - Aug 2010

Fingerprint

Neuroblastoma
Heterografts
Rhabdomyosarcoma
Pediatrics
Viruses
Tumor Burden
Virion
Alveolar Rhabdomyosarcoma
Rhabdoid Tumor
Cell Line
Clinical Trials, Phase I
Neuroendocrine Tumors
Wilms Tumor
RNA Viruses
Glioblastoma
Coma
Disease-Free Survival
Neoplasms
In Vitro Techniques

Keywords

  • Developmental therapeutics
  • Preclinical testing
  • Seneca Valley virus (NTX-010)

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Morton, C. L., Houghton, P. J., Kolb, E. A., Gorlick, R., Reynolds, C. P., Kang, M. H., ... Smith, M. A. (2010). Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 55(2), 295-303. https://doi.org/10.1002/pbc.22535

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. / Morton, Christopher L.; Houghton, Peter J.; Kolb, E. Anders; Gorlick, Richard; Reynolds, C. Patrick; Kang, Min H.; Maris, John M.; Keir, Stephen T.; Wu, Jianrong; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 55, No. 2, 08.2010, p. 295-303.

Research output: Contribution to journalArticle

Morton, CL, Houghton, PJ, Kolb, EA, Gorlick, R, Reynolds, CP, Kang, MH, Maris, JM, Keir, ST, Wu, J & Smith, MA 2010, 'Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 55, no. 2, pp. 295-303. https://doi.org/10.1002/pbc.22535
Morton, Christopher L. ; Houghton, Peter J. ; Kolb, E. Anders ; Gorlick, Richard ; Reynolds, C. Patrick ; Kang, Min H. ; Maris, John M. ; Keir, Stephen T. ; Wu, Jianrong ; Smith, Malcolm A. / Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2010 ; Vol. 55, No. 2. pp. 295-303.
@article{c9de2d819f6644a4b4c1c4ba30fc2e3f,
title = "Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program",
abstract = "Background. Seneca Valley virus (NTX-010) is a nonrecombinant, replication competent RNA virus that is undergoing phase 1 clinical trials in adults for tumors with neuroendocrine characteristics. Here we have evaluated the antitumor activity of NTX-010 administered systemically. Procedures. In vitro NTX-010 was tested against 23 cell lines exposed for 96 hr at 1 × 10-4 to 104 viral particles (vp)/cell. In vivo NTX-010 was administered intravenously once at 3 × 1012 vp/kg. Three measures of antitumor activity were used: (1) an objective response measure modeled after the clinical setting; (2) a treated to control (T/C) tumor volume measure; and (3) a time to event (fourfold increase in tumor volume for solid tumor models), measure based on the median event-free survival (EFS) of treated and control animals for each xenograft. Results. In vitro NTX-010 demonstrated a marked cytotoxic effect in a subset of the cell lines from the neuroblastoma, Ewingsar coma, and rhabdomyosarcoma panels. In vivo the most consistent activitywas observed for the rhabdomyosarcoma and the neuroblastoma panels, with all four of the alveolar rhabdomyosarcoma xenografts and four of five neuroblastoma xenografts achieving CR or maintained CR. Objective responses were also observed in the rhabdoid tumor,Wilms tumor, and glioblastoma panels. Conclusions. NTX-010 demonstrated a high level of activity both in vitro and in vivo. Further analysis of existingtestingand molecular characterization data may help define the biological characteristics of cancer cells that are associated with response to NTX-010.",
keywords = "Developmental therapeutics, Preclinical testing, Seneca Valley virus (NTX-010)",
author = "Morton, {Christopher L.} and Houghton, {Peter J.} and Kolb, {E. Anders} and Richard Gorlick and Reynolds, {C. Patrick} and Kang, {Min H.} and Maris, {John M.} and Keir, {Stephen T.} and Jianrong Wu and Smith, {Malcolm A.}",
year = "2010",
month = "8",
doi = "10.1002/pbc.22535",
language = "English (US)",
volume = "55",
pages = "295--303",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program

AU - Morton, Christopher L.

AU - Houghton, Peter J.

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Maris, John M.

AU - Keir, Stephen T.

AU - Wu, Jianrong

AU - Smith, Malcolm A.

PY - 2010/8

Y1 - 2010/8

N2 - Background. Seneca Valley virus (NTX-010) is a nonrecombinant, replication competent RNA virus that is undergoing phase 1 clinical trials in adults for tumors with neuroendocrine characteristics. Here we have evaluated the antitumor activity of NTX-010 administered systemically. Procedures. In vitro NTX-010 was tested against 23 cell lines exposed for 96 hr at 1 × 10-4 to 104 viral particles (vp)/cell. In vivo NTX-010 was administered intravenously once at 3 × 1012 vp/kg. Three measures of antitumor activity were used: (1) an objective response measure modeled after the clinical setting; (2) a treated to control (T/C) tumor volume measure; and (3) a time to event (fourfold increase in tumor volume for solid tumor models), measure based on the median event-free survival (EFS) of treated and control animals for each xenograft. Results. In vitro NTX-010 demonstrated a marked cytotoxic effect in a subset of the cell lines from the neuroblastoma, Ewingsar coma, and rhabdomyosarcoma panels. In vivo the most consistent activitywas observed for the rhabdomyosarcoma and the neuroblastoma panels, with all four of the alveolar rhabdomyosarcoma xenografts and four of five neuroblastoma xenografts achieving CR or maintained CR. Objective responses were also observed in the rhabdoid tumor,Wilms tumor, and glioblastoma panels. Conclusions. NTX-010 demonstrated a high level of activity both in vitro and in vivo. Further analysis of existingtestingand molecular characterization data may help define the biological characteristics of cancer cells that are associated with response to NTX-010.

AB - Background. Seneca Valley virus (NTX-010) is a nonrecombinant, replication competent RNA virus that is undergoing phase 1 clinical trials in adults for tumors with neuroendocrine characteristics. Here we have evaluated the antitumor activity of NTX-010 administered systemically. Procedures. In vitro NTX-010 was tested against 23 cell lines exposed for 96 hr at 1 × 10-4 to 104 viral particles (vp)/cell. In vivo NTX-010 was administered intravenously once at 3 × 1012 vp/kg. Three measures of antitumor activity were used: (1) an objective response measure modeled after the clinical setting; (2) a treated to control (T/C) tumor volume measure; and (3) a time to event (fourfold increase in tumor volume for solid tumor models), measure based on the median event-free survival (EFS) of treated and control animals for each xenograft. Results. In vitro NTX-010 demonstrated a marked cytotoxic effect in a subset of the cell lines from the neuroblastoma, Ewingsar coma, and rhabdomyosarcoma panels. In vivo the most consistent activitywas observed for the rhabdomyosarcoma and the neuroblastoma panels, with all four of the alveolar rhabdomyosarcoma xenografts and four of five neuroblastoma xenografts achieving CR or maintained CR. Objective responses were also observed in the rhabdoid tumor,Wilms tumor, and glioblastoma panels. Conclusions. NTX-010 demonstrated a high level of activity both in vitro and in vivo. Further analysis of existingtestingand molecular characterization data may help define the biological characteristics of cancer cells that are associated with response to NTX-010.

KW - Developmental therapeutics

KW - Preclinical testing

KW - Seneca Valley virus (NTX-010)

UR - http://www.scopus.com/inward/record.url?scp=77955122126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955122126&partnerID=8YFLogxK

U2 - 10.1002/pbc.22535

DO - 10.1002/pbc.22535

M3 - Article

C2 - 20582972

AN - SCOPUS:77955122126

VL - 55

SP - 295

EP - 303

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -